Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epileptic/Seizure Foci Clear all
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

Buspirone Therapy for Localized Epilepsy

NCT01496612
View directory record Official record
Conditions
Anxiety Disorder, Seizures, Epilepsy, Partial Epilepsy, Depression
Interventions
Buspirone, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Jul 23, 2026, 5:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain P-gp and Inflammation in People With Epilepsy

NCT01663545
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Withdrawn Phase 3 Interventional

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

NCT03108729
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Henderson, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 2Phase 3 Interventional

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902
View directory record Official record
Conditions
Focal Seizure
Interventions
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Phoenix, Arizona • DeLand, Florida • Miami Lakes, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Withdrawn Not applicable Interventional

Turmeric as Treatment in Epilepsy

NCT03254680
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, Focal Seizures
Interventions
Turmeric
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

NCT04770337
View directory record Official record
Conditions
Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Interventions
STARSTIM device, Sham Device
Device
Lead sponsor
Neuroelectrics Corporation
Industry
Eligibility
9 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
XEN1101, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Enrolling by invitation Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

NCT07353918
View directory record Official record
Conditions
Epilepsy (Treatment Refractory), Epilepsy Comorbidities
Interventions
Low-intensity Focused Ultrasound, Sham
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting No phase listed Observational

Links Between Epileptic Activity, Sleep Disruption and Mental Content During Sleep

NCT07605858
View directory record Official record
Conditions
Patients With Drug-resistant Focal Epilepsy, SEEG as Part of Presurgical Evaluation
Interventions
Direct Electric Stimulation (DES)
Other
Lead sponsor
Hospices Civils de Lyon
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

NCT03739840
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions
Padsevonil, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
32
States / cities
Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 23, 2026, 5:00 PM EDT
Completed No phase listed Observational

Human Epilepsy Project 2: Resistant Focal Seizures Study

NCT03531008
View directory record Official record
Conditions
Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
Interventions
Not listed
Lead sponsor
Epilepsy Foundation of America
Other
Eligibility
16 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Not yet recruiting Phase 4 Interventional

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

NCT06534502
View directory record Official record
Conditions
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
Interventions
Zonisamide Oral Product
Drug
Lead sponsor
Azurity Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Port Charlotte, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Not applicable Interventional

Study of Transcranial Direct Current Stimulation to Treat Epilepsy

NCT05673915
View directory record Official record
Conditions
Focal Epilepsy, Generalized Onset Epilepsy, Sleep-related Epileptic Encephalopathy
Interventions
ActivaDose II 0.1 mA transcranial direct current stimulation (tDCS), ActivaDose II 2.0 mA transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 4 Interventional Results available

BOTOX Effects on Seizure Severity and Susceptibility

NCT05605756
View directory record Official record
Conditions
Drug-resistant Focal Seizure
Interventions
OnabotulinumtoxinA 145 UNT [Botox]
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 3 Interventional

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

NCT05614063
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
XEN1101, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
56
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional

Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

NCT07505004
View directory record Official record
Conditions
Focal Epilepsy
Interventions
40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Miami, Florida • Miami Lakes, Florida • Naples, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional

Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).

NCT06051448
View directory record Official record
Conditions
Mitochondrial Diseases, Mitochondrial Myopathies, Mitochondrial Encephalomyopathies, MELAS, MERRF
Interventions
Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN)
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Completed No phase listed Observational Results available

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

NCT02392078
View directory record Official record
Conditions
Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
Not listed
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 2 Interventional

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

NCT07141329
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Port Charlotte, Florida
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966
View directory record Official record
Conditions
Focal Epilepsy
Interventions
BHV-7000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 5:00 PM EDT